Ahmad S. Halwani,
MD
Languages Spoken: English
Labs: Website
Dr. Ahmad Halwani is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies in the Department of Internal Medicine at the University of Utah and a clinical investigator at the Huntsman Cancer Institute (HCI). He is also a staff physician and clinical researcher at the George E Whalen Veterans Health Administration (VHA) in Salt Lake City. Dr. Halwani’s practice at Huntsman Cancer Institute focuses on lymphoid malignancies, specifically Lymphoma and Chronic Lymphocytic Leukemia (CLL). Dr. Halwani was also responsible for leading an effort to establish the first lymphoid malignancy focused clinic at the George E Whalen VHA where Veterans with Lymphoma and CLL can receive sub-specialty focused care.
For questions regarding Dr. Halwani's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at www.huntsmancancer.org or (801) 585-6906.
Clinical Locations
Clinic 2D/E BMT/Hematology-Malignant
801-585-2626
Fax: (801) 581-8163
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor (Clinical) |
| Academic Divisions | Hematology/BMT |
| Board Certification | American Board of Internal Medicine (Sub: Medical Oncology) Educational Commission for Foreign Medical Graduates |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.9/ 5
Care provider's explanation of condition/problem
4.8/ 5
Care provider's effort to include me in decisions
4.8/ 5
Wait time at clinic
4.5/ 5
Care provider's concern for questions & worries
4.8/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
February 21, 2022
HUNTSMAN CANCER CENTER
Dr. Halwani is an exceptional Doctor. We trust his expertise, he explains the different results in a manner we can understand, tells us the different options available in dealing with the different issues. Truly thankful for being under his medical care.
UofU Patient
December 09, 2021
HUNTSMAN CANCER CENTER
The doctor was very attentive. He listened and answered all my questions fully and in a way I could understand.
UofU Patient
September 15, 2021
HUNTSMAN CANCER CENTER
Dr. Halwani was outstanding in regards to providing information and listening to my concerns. The atmosphere was relaxed and friendly while very professional.
UofU Patient
April 04, 2021
HUNTSMAN CANCER CENTER
I was glad that he listened to my concerns and gave me some help in areas where I felt previous providers didn't show concern.
UofU Patient
March 21, 2021
HUNTSMAN CANCER CENTER
very informative
UofU Patient
November 22, 2020
HUNTSMAN CANCER CENTER
very helpful explanations of possibilities
UofU Patient
August 27, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
August 05, 2020
HUNTSMAN CANCER CENTER
Really impressed with the staff and Jess and DR Hawanii
Dr. Ahmad Halwani is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies in the Department of Internal Medicine at the University of Utah and a clinical investigator at the Huntsman Cancer Institute (HCI). He is also a staff physician and clinical researcher at the George E Whalen Veterans Health Administration (VHA) in Salt Lake City. Dr. Halwani’s practice at Huntsman Cancer Institute focuses on lymphoid malignancies, specifically Lymphoma and Chronic Lymphocytic Leukemia (CLL). Dr. Halwani was also responsible for leading an effort to establish the first lymphoid malignancy focused clinic at the George E Whalen VHA where Veterans with Lymphoma and CLL can receive sub-specialty focused care.
For questions regarding Dr. Halwani's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at http://www.huntsmancancer.org or (801) 585-6906.
Academic Locations
Veterans Administration Medical Center
801-585-2626
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor (Clinical) |
| Academic Divisions | Hematology/BMT |
| Board Certification | American Board of Internal Medicine (Sub: Medical Oncology) Educational Commission for Foreign Medical Graduates |
Education History
| Fellowship | University of Iowa Hospitals & Clinics Medical Oncology Fellow, 2011 |
| Fellowship | University of Iowa Hospitals & Clinics Allergy and Immunology Fellow, 2009 |
| Residency | University of Iowa Hospitals & Clinics Internal Medicine Resident, 2007 |
| Professional Medical | American University of Beirut Medicine M.D., 2003 |
| Undergraduate | American University of Beirut Biology with High Distinction B.S., 1999 |
Selected Publications - Journal Articles
Journal Article
- Chien HC, Morreall D, Patil V, Rasmussen KM, Yong C, Li C, Passey DG, Burningham Z, Sauer BC, Halwani AS (2021). Treatment Patterns and Outcomes in a Nationwide Cohort of Older and Younger Veterans with Waldenström Macroglobulinemia, 2006-2019. Cancers (Basel), 13(7).
- Li C, Patil V, Rasmussen KM, Yong C, Chien HC, Morreall D, Humpherys J, Sauer BC, Burningham Z, Halwani AS (2021). Predicting Survival in Veterans with Follicular Lymphoma Using Structured Electronic Health Record Information and Machine Learning. Int J Environ Res Public Health, 18(5).
- Chien HC, Morreall D, Patil V, Rasmussen KM, Li C, Yong CM, Burningham Z, Masaquel A, Halloran M, De Long-Sieg E, Schulz M, Sauer BC, Halwani AS (2020). Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma. Future Oncol, 17(4), 411-422.
- Passey DG, Healy R, Qualls J, Halwani A, Sauer BC (2020). Pharmacist-led collaborative medication management programs for oral antineoplastic therapies: A systematic literature review. J Am Pharm Assoc (2003), 61(3), e7-e18.
- Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kim YH, Mehta-Shah N, Olsen EA, Pro B, Rajguru SA, Rozati S, Said J, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H (2020). NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. J Natl Compr Canc Netw, 18(11), 1460-1467.
- Halwani AS, Rasmussen KM, Patil V, Morreall D, Li C, Yong C, Burningham Z, Dawson K, Masaquel A, Henderson K, DeLong-Sieg E, Sauer BC (2020). Maintenance rituximab in Veterans with follicular lymphoma. Cancer Med, 9(20), 7537-7547.
- Richter Lagha R, Burningham Z, Sauer BC, Leng J, Peters C, Huynh T, Patel S, Halwani AS, Kramer BJ (2020). Usability Testing a Potentially Inappropriate Medication Dashboard: A Core Component of the Dashboard Development Process. Appl Clin Inform, 11(4), 528-534.
- Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Fisher K, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Lunning MA, Mehta A, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H, Kim YH (2020). NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. J Natl Compr Canc Netw, 18(5), 522-536.
- Rasmussen KM, Patil V, Burningham Z, Yong C, Sauer BC, Halwani AS (2020). Atrial Fibrillation and Bleeding in Patients With Chronic Lymphocytic Leukemia Treated with Ibrutinib in the Veterans Health Administration. Fed Pract, 37(Suppl 2), S44-S49.
- Halwani AS, Rasmussen KM, Patil V, Li CC, Yong CM, Burningham Z, Gupta S, Narayanan S, Lin SW, Carroll S, Mhatre SK, Graff JN, Dreicer R, Sauer BC (2019). Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urol Oncol, 38(1), 1.e1-1.e10.
- Walsh JA, Pei S, Penmetsa GK, Sauer BC, Patil V, Walker JH, Clewell J, Douglas KM, Clegg DO, Cannon GW, Halwani A (2019). Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis. J Manag Care Spec Pharm, 25(11), 1218-1228.
- Burningham Z, Chen W, Sauer BC, Richter Lagha R, Hansen J, Huynh T, Patel S, Leng J, Halwani A, Kramer BJ (2019). VA Geriatric Scholars Program's impact on prescribing potentially inappropriate medications. Am J Manag Care, 25(9), 425-430.
- Peters CB, Hansen JL, Halwani A, Cho ME, Leng J, Huynh T, Burningham Z, Caloyeras J, Matsuda T, Sauer BC (2019). Validation of Algorithms Used to Identify Red Blood Cell Transfusion Related Admissions in Veteran Patients with End Stage Renal Disease. EGEMS (Wash DC), 7(1), 23.
- Elkeeb D, Hopkins Z, Miles RR, Halwani A, Wada D (2019). Ominous cutaneous presentation of acute myeloid leukemia without peripheral blood involvement upon initial presentation and relapse: case report and literature review. Eur J Dermatol, 28(6), 809-817.
- Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M, MAVORIC Investigators (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol, 19(9), 1192-1204.
- Burningham Z, Leng J, Peters CB, Huynh T, Halwani A, Rupper R, Hicken B, Sauer BC (2018). Predicting Psychiatric Hospitalizations among Elderly Veterans with a History of Mental Health Disease. EGEMS (Wash DC), 6(1), 7.
- Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer MA, Sundar H (2018). NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. J Natl Compr Canc Netw, 16(2), 123-135.
- Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, Avigdor A, Halwani AS, Houot R, Marchand T, Dhedin N, Lescaut W, Thiebaut-Bertrand A, Franois S, Stamatoullas-Bastard A, Rohrlich PS, Labussire Wallet H, Castagna L, Santoro A, Bachanova V, Bresler SC, Srivastava A, Kim H, Pesek E, Chammas M, Reynolds C, Ho VT, Antin JH, Ritz J, Soiffer RJ, Armand P (2017). Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood, 129(10), 1380-1388.
- Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW (2016). Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation. Oncology (Williston Park), 30(11), 970-4, 980-1, C3.
- Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J (2016). Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol, 34(23), 2698-704.
- McPherson JP, Vrontikis A, Sedillo C, Halwani AS, Gilreath JA (2016). Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions. Pharmacotherapy, 36(2), e8-e11.
- Colonna S, Halwani A, Ying J, Buys S, Sweeney C (2015). Women with breast cancer in the Veterans Health Administration: demographics, breast cancer characteristics, and trends. Med Care, 53(4 Suppl 1), S149-55.
- Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med, 372(4), 311-9.
- Nelson SD, Lu CC, Teng CC, Leng J, Cannon GW, He T, Zeng Q, Halwani A, Sauer B (2015). The use of natural language processing of infusion notes to identify outpatient infusions. Pharmacoepidemiol Drug Saf, 24(1), 86-92.
- Ontiveros EP, Halwani A, Stunz LL, Kamberos N, Olivier AK, Janz S, Bishop GA (2014). A new model of LMP1-MYC interaction in B cell lymphoma. Leuk Lymphoma, 55(12), 2917-23.
- Han SS, Tompkins VS, Son DJ, Kamberos NL, Stunz LL, Halwani A, Bishop GA, Janz S (2013). Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells. Biochem Biophys Res Commun, 436(4), 660-5.
- Halwani AS, Link BK (2011). Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. Expert Rev Anticancer Ther, 11(3), 443-55.
- Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, Weiner GJ (2008). A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res, 14(20), 6697-703.
Letter
- Chien HC, Morreall D, Patil V, Rasmussen KM, Yong CM, Li CY, Passey DG, Burningham Z, Sauer BC, Halwani AS (2021). Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019. [Letter to the editor]. Am J Hematol, 96(6), E184-E187.
- Laggis CW, Lamb A, Secrest AM, Ufkes N, Halwani AS, Tao R, Gaffney D, Miles RR, Florell SR, Wada D (2020). Favourable outcomes in folliculotropic mycosis fungoides after multimodality treatment in a single institution. [Letter to the editor]. J Eur Acad Dermatol Venereol, 35(1), e42-e45.
Abstract
- Kim YH, Bagot M, Eradat HA, Carson KR, Greer JP, Kim EJ, Kuzel T, Hughey LC, Poligone B, Lansigan F, Zinzani PL, Grandinetti LM, Procu P, Shustov AR, Korman NJ, Halwani A, Sokol L, Duvic M (01012014). Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab vs vorinostat in relapsed or refractory cutaneous t-cell lymphoma (CTCL). [Abstract]. J Clinical Oncology American Society of Clinicial Oncology annual meeting.
- Lesokhin A, Gutierrez M, Halwani A, Ansell SM, Armand P, Borrello I, Segota ZE, Cohen AD, Talpaz M, Cattry D, Turner T, Mezes M, Hartman C, Gupta A, Kim SY, Wigginton JM, Timmerman JM (01012014). A Phase 1 Dose Escalation Study Evaluating the Effects of Nivolumab (anti-PD-1; BMS-936558) in Patients with Select Relapsed or Refractory Hematologic Malignancies. [Abstract]. J Clinical Oncology American Society of Clinicial Oncology annual meeting.
- Halwani A, Stunz S, Hu L, Janz S, Bishop G (2010). A new mouse lymphoma model, the iMycEµ-LMP1 transgenic mouse, suggests collaboration of LMP1 and Myc in lymphomagenesis. Poster Presentation; University of Iowa Carver College of Medicine, College of Pharmacy, College of Public Health, Institute for Clinical and Translational Science and VA Health System Research Week. [Abstract].
- Halwani A, Ballas Z (2009). Progression of Selective IgM Deficiency to Common Variable Immunodeficiency. Journal of Allergy and Clinical Immunology. Poster Presentation, AAAAI annual meeting [Abstract]. 123(2, Supplement 1), S89.
- Halwani A (2008). Eczematous Rash, Elevated IgE & Recurrent Infections. Presented at the Clinical Immunology Society Primary Immunodeficiency Summer School. [Abstract].
- Halwani A, Ballas Z (2008). Delayed Recovery of T Cell Response Post Cyclosporin Therapy. Journal of Allergy and Clinical Immunology. Poster Presentation, AAAAI annual meeting. [Abstract]. 121(2, Supplement 1), S87.
- Halwani A, Gingrich R (2005). An Unusual Tonsillitis. American College of Physicians, Iowa Chapter, Associates Clinical Vignette Competition. [Abstract].
Global Impact
Education History
| Professional Medical | American University of Beirut Medicine M.D. |
| Undergraduate | American University of Beirut Biology with High Distinction B.S. |